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Abstract 
Patient preference predictors aim to solve the moral problem of making 
treatment decisions on behalf of incapacitated patients. This 
commentary on a case of an unrepresented patient at the end of life 
considers 3 related problems of such predictors: the problem of 
restricting the scope of inputs to the models (the “scope” problem), the 
problem of weighing inputs against one another (the “weight” problem), 
and the problem of multiple reasonable solutions to the scope and 
weight problems (the “multiple reasonable models” problem). Each of 
these problems poses challenges to reliably implementing patient 
preference predictors in important, high-stakes health care decision 
making. This commentary also suggests a way forward. 
 
Case 
Mr T is an 88-year-old black man with squamous cell carcinoma of the throat metastatic 
to the brain, complicated by recurrent seizures. The patient is admitted from his medical 
care facility because he is no longer able to swallow due to tumor progression, and there 
is concern for pending airway occlusion. Mr T’s wife passed away many years ago and he 
has no children, other family, or friends. Mr T has had altered mental status, likely due to 
the brain metastases and recurrent seizures. He is unable to speak and intermittently 
makes uninterpretable vocalizations. The oncology team is not offering to continue Mr 
T’s treatment and has predicted that he will likely die within weeks without 
interventions, such as a percutaneous endoscopic gastrostomy (PEG) tube and 
tracheostomy, and in less than 6 months in any case. 
 
In a multidisciplinary meeting, Dr J references an article featuring a predictive model that 
shows that being black is consistently associated with preferring more end-of-life 
treatment in medical settings.1,2 Dr J asks, “Should we conclude from this article that Mr 
T would want a PEG tube and tracheostomy?” Dr O, an oncologist, voices doubt about 
applying population-level data to decisions involving particular patients. Dr J says, “Yes, I 
wondered about that, too.” He then mentions a study showing that 78.9% of patients 
would prefer to have aggregate data incorporated into processes of making clinical 
decisions on their own behalf.3 They further discuss and wonder what to do. 
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Commentary 
Care for incapacitated patients generates familiar moral problems. Foremost among 
these is the problem of making treatment decisions on their behalf. The cause of the 
problem is obvious. Typically, medical professionals defer to a patient’s (informed) 
decisions, but an incapacitated patient clearly can’t make the relevant treatment 
decisions. What to do? The obvious thing to do is for medical professionals to defer to 
some other source with the moral standing to speak on behalf of the incapacitated 
patient.  
 
Traditionally, the sources thought to have the moral standing to direct treatment on 
behalf of incapacitated patients are of 2 broad sorts: advance directives and surrogates. 
In an advance directive, a patient expresses her preferences over a range of treatment 
decisions in advance of her incapacitation. It’s obvious why advance directives plausibly 
have the relevant sort of moral standing: deferring to a patient’s advance directive is a 
way of deferring to that patient’s own decisions at one remove, as it were.4-7 In surrogate 
decision making, third parties make treatment decisions on behalf of the incapacitated 
patient. These surrogates are supposed to have the relevant moral standing either 
because of a formal relationship—say, medical power of attorney—or because of a 
more informal relationship that intuitively justifies such moral standing—say, in the 
absence of medical power of attorney, the surrogate’s being a spouse or an adult child. 
(Of course, the two often go together, as relatives make natural candidates for power of 
attorney.)8,9 
 
Recently, a third source of moral standing for making treatment decisions on behalf of 
incapacitated patients has been proposed: so-called patient preference predictors 
(henceforth, PPPs).1,10,11 Very briefly, PPPs are statistical models that predict the 
treatment preferences of a patient described by a combination of known demographic 
variables—such as age, educational level, religion, and so on—based on aggregate data 
about the treatment preferences of persons with demographic profiles similar to the 
patient.12-14 Before turning to the moral standing of PPPs, let me mention one issue in 
order to set it firmly aside in what follows. One immediate reaction to the suggestion 
that we predict an incapacitated patient’s preferences using patient demographic 
descriptors that are likely to be known—especially, race, gender, and age—is that it’s 
radically unclear how robust such predictions might be. The first thing to say in response 
is that there are in fact some broad, relatively strong correlations between such factors 
and, for instance, preferences for palliative care at the end of life.15 Now, it’s true that we 
lack the kind of broad-based statistical data over a range of treatment options that 
would be necessary to make PPPs widely useful in a clinical context. But it’s trivial to 
imagine how we might go about acquiring such data. For instance, Rid and Wendler 
propose a national PPP survey of competent adults that could be used to correlate the 
most likely relevant demographic descriptors with patients’ preferences over a wide 
range of treatment options in a wide range of scenarios.1 There are other possibilities, 
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too. In any case, this practicability question isn’t one that I’ll be concerned with in what 
follows. 
 
So, why think PPPs have any moral standing to determine treatment decisions on behalf 
of patients? The intuitive argument is straightforward. Recall that the best-case scenario 
is one in which a patient’s treatment reflects her own informed decisions. Advance 
directives and surrogates are ways of trying to epistemically access—in more or less 
direct ways—what we think those informed decisions would have been. Moreover, that 
they are directed toward the patient’s own preferences is what explains why they have 
the kind of moral standing they do in the process of making treatment decisions on 
behalf of incapacitated patients. Likewise, the use of PPPs is a way of trying to 
epistemically access an incapacitated patient’s own preferences with respect to her 
treatment. Intuitively, then, if advance directives and surrogates enjoy the relevant sort 
of standing, then PPPs ought to enjoy that same standing. 
 
In any case, I’m going to assume we’re sometimes justified in using PPPs to make 
treatment decisions on behalf of incapacitated patients. This assumption is compatible 
with restrictions on their permissible use—perhaps we think they can only be used to 
supplement surrogate decision making or that they can only be used in the absence of 
both an advance directive and a suitable surrogate.12 These restrictions won’t concern 
me here. Instead, my interest is more narrowly focused on conceptual challenges to 
reliably implementing patient preference predictors in such high-stakes health care 
decision making.  
 
Suppose we are justified in sometimes using PPPs; there are 2 interesting problems that 
arise in the context of using PPPs that don’t arise for advance directives or surrogates. 
(There are, of course, other problems. For instance, Rid and Wendler1—2 proponents of 
the use of PPPs—point to the danger of stereotyping inherent in this sort of statistical 
model using readily apparent demographic descriptors. In other work,12 I’ve also argued 
that PPPs face a closely related problem—analogous to a familiar problem in legal 
scholarship—having to do with moving from bare statistical evidence to normative 
conclusions. These problems, while important, won’t concern me here.) I’ll argue that the 
presence of these 2 interesting problems generates a third, quite serious difficulty for 
the use of PPPs in a clinical setting. I’ll then close by briefly explaining one strategy for 
solving this third difficulty as a way of laying out a fruitful direction for future research. 
But first, I discuss the 2 initial problems. 
 
Two Initial Problems With PPPs 
The scope problem. Recall that a PPP can usefully be thought of as a function that takes 
as input known characteristics of the patient and produces a probabilistic prediction 
regarding the patient’s preference for (or against) a particular medical intervention based 
on aggregate data from people who share similar characteristics with the patient. Not all 
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known information about a patient ought to be used in producing these probabilistic 
predictions. In particular, we ought to exclude uncontroversially false (but suitably 
important) normative beliefs that might be correlated with patients’ preferences, and we 
ought to exclude some (but not all) normatively irrelevant characteristics of patients that 
might be correlated with patients’ preferences. Hence the scope problem. The scope 
problem is the problem of restricting, in a principled way, what sort of information can be 
used as inputs to a PPP. Let me comment briefly on false normative beliefs and 
irrelevant characteristics as a way of making intuitive the case that these inputs ought to 
be excluded from PPPs. 
 
Take false normative beliefs first. Suppose we knew that victims of long-term domestic 
abuse were much less likely to prefer palliative care in particular circumstances. Suppose 
further that we had a normative explanation of this fact, viz, that victims of domestic 
abuse have a diminished sense of their own worth as compared to the worth of others—
they (incorrectly) believe that they somehow “deserve” suffering or that their suffering 
somehow counts for less. I take it for granted that we would want to exclude such a false 
belief from our PPP when using it to deliver a verdict regarding a patient’s preferences in 
treatment. The argument for this claim is straightforward; spelling it out in detail would 
require too much space in the present context. Roughly, you can’t derive a correct 
normative verdict regarding how you ought to treat a patient, ie, what medical treatment 
to provide to her, from that patient’s preference grounded in a manifestly false 
normative belief, ie, that her suffering is less morally important than others’.  
 
Now take normatively irrelevant facts about patients. We know that religion is strongly 
correlated with preferences regarding end-of-life care.16 And religious identity is 
precisely the kind of thing we intuitively want to include as input to a PPP. So far, so 
good. But now notice that there’s nothing that rules out the possibility that (say) whether 
one prefers the NFL to the NBA correlates quite strongly with one’s preferences 
regarding end-of-life care. One response would be to simply include that sports 
preference among the demographic descriptors that, if known, could be used by a PPP to 
predict a patient’s preferences over the relevant treatment options. But this is strongly 
counterintuitive. While there doesn’t appear to be any—or, at least, much—intuitive 
resistance to taking religion as a relevant input to a model designed to predict what an 
incapacitated patient would want, there is a strong intuitive case against taking 
sportsball preference into account in the same way. Again, spelling out the details of this 
argument would require too much space in the present context, but here, roughly, is the 
idea. Some facts about one’s self are more or less central to one’s identity. And when it 
comes to making life-altering—and potentially life-ending—decisions, it’s perfectly 
natural to want those decisions to be made on the basis of those facts about one’s self 
that are central—for most people, their religious identity—rather than on the basis of 
those facts that float around the periphery—again, for most people, their preferring the 
NBA to the NFL, or vice versa. 
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Hence, the scope problem is this: How should we restrict, in a principled way, the sort of 
information that can be appropriately used as the input to a PPP? (If you’re not 
particularly bothered by this problem because you think it’s obvious that all information 
ought to be allowed as input to a PPP, the scope problem still generates the problem 
that below I call the multiple models problem.) 
 
The weight problem. The second problem is what I’ll call the weight problem. The weight 
problem is the problem of explaining, in a principled way, how to correctly weight the 
information that serves as input to a PPP. Even if we have a solution to the scope 
problem in hand, this solution does not tell us how to weight the various inputs to a PPP 
in coming to a final verdict. For instance, while we might agree that (say) someone’s 
ethnicity ought to serve as input to a PPP, you might think that predictions based on 
ethnicity ought to be weighted less as compared to (say) predictions based on religion, 
and I might think the opposite. This disagreement over the correct weight assignment for 
these 2 factors could obviously lead to disagreement over the correct treatment 
decision. (And assuming there’s some fact of the matter about how we ought in fact to 
treat the patient, it can lead predictably to patient harm.) 
 
One natural response to this problem is to posit that there is some objective principle for 
weighting the inputs to the PPP that assigns some specific weight to each—0.3 to 
ethnicity, 0.6 to religion, say. But it’s hard to see what the principled way of determining 
the values of such an objective weighting might be. (This is what I meant, above, in 
saying that the problem was one of explaining in a principled way how to weight the 
various inputs to a PPP.) The difficulty arises because it’s hard to imagine what sort of 
data we could acquire—either by sampling existing data or by gathering new data—that 
would lead us to reasonably conclude that always, everywhere, for patients who are 
(say) both Asian and Catholic, their ethnicity ought to be weighted (say) ⅓ as much as 
their religion. This is not to say that we might not gain some information that would lead 
us to a range of likely values for these relative weights. But then we face the multiple 
models problem, which I’ll turn to now. 
 
Multiple reasonable models problem. In order for the use of PPPs in a clinical context to be 
morally permissible, the scope and the weight problems require solutions; as yet, they 
have none. But things are even more complicated than this. For, together with some 
commonsense observations about the difficulty of the issues involved, these problems 
generate what I’ll call the multiple reasonable models problem. The multiple reasonable 
models problem is this: there will be reasonable disagreement over how to solve the 
scope and the weight problems. 
 
A very quick word about reasonable disagreement. To say that these disagreements are 
reasonable is to say that well-informed persons reasoning together in good faith over 
what information should be included in our PPPs (the scope problem) and how to weight 
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that information (the weight problem) could in principle continue to disagree and that 
neither need be making a normative or nonnormative mistake correctable by further 
analysis of the values at stake or the data available.15 Such reasonable disagreement is 
presumably due to what John Rawls calls, in a related context, the very difficult “burdens 
of judgment” when it comes to normative questions.17 The sort of reasonable 
disagreement I have in mind is analogous to (indeed, might be a species of) Rawls’s idea 
of reasonable disagreement in a liberal political society over what comprehensive 
doctrine is correct. In the present context, the claim is not that the presence of 
reasonable disagreement informs the correct political arrangement; instead, it is simply 
that in virtue of reasonable people’s reasonable disagreement over the correct 
“comprehensive doctrine,” there will be downstream reasonable disagreement over how 
to solve the scope and weight problems, ie, disagreement over what factors ought to be 
used in predicting agents’ preferences and how to weight those factors. This is not to say 
that all such disagreement over how to solve these problems would be reasonable. This 
is just to say that some such disagreement would be. 
 
But, then, given that some such disagreement is reasonable, in clinical contexts medical 
professionals will be forced to decide between equally reasonable PPPs that deliver 
equally reasonable but incompatible verdicts regarding patients’ preferences, ie, each 
PPP is an equally reasonable function that takes us from known information about a 
patient to (competing) verdicts regarding her preferences for medical treatments. Hence, 
the multiple reasonable models problem arises.  
 
We can see that the scope problem allows for reasonable disagreement by focusing on 
either of the 2 illustrations of it I offered above: the case of false normative beliefs and 
the case of normatively irrelevant facts about patients. I offered what I took to be 
uncontroversial instances of the sorts of things we want to exclude from our PPP: on the 
one hand, the correlation between patients’ normatively false belief that they don’t merit 
care (because of being victims of domestic abuse) and their care preferences, and, on the 
other hand, the correlation between patients’ normatively irrelevant preference for the 
NBA over the NFL and their care preferences. But it should be obvious that there can be 
reasonable disagreement of the sort just described over both these types of cases. For 
instance, you and I might reasonably disagree over whether some patient’s normative 
belief is actually false or not; or we might disagree over whether this or that 
characteristic is suitably central to patient identity to merit inclusion in the PPP. 
 
To see that the weight problem allows for reasonable disagreement, notice that even if 
we agree on whether to allow both ethnic and religious identity to inform our PPP, we 
might reasonably disagree over how to weight those factors. Returning to the discussion 
above, you might think we ought to assign ethnicity a weight ⅓ that of religion in the 
present context; I might disagree. This disagreement would not be unreasonable; 
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instead, it would presumably be due to what is itself reasonable disagreement on how to 
value religious as compared to ethnic identity.  
 
The multiple models problem is hence where the scope and the weight problems truly 
earn their keep: what these observations show is that, even assuming we’ve provided 
some solution or other to the scope and weight problems, this solution will just be one 
among several reasonable alternative solutions. Hence medical professionals will still 
face reasonable disagreement over what PPP to use; in a clinical context, this is a real 
barrier to the use of PPPs in making treatment decisions on behalf of incapacitated 
patients.  
 
Prospects for Solving the Multiple Reasonable Models Problem 
Let me close with a couple of quick remarks on how I think we should move forward. We 
can begin by noticing that there appears to be an analog of the multiple reasonable 
models problem when it comes to the use of surrogates. This is clearest in the absence 
of a patient’s formal designation of a surrogate: in that case, it’s possible for reasonable 
people to reasonably disagree over who should serve as the patient’s surrogate. For 
instance, we might reasonably disagree over whether it should be (say) the patient’s 
relatively new spouse or her adult child. When this happens, we appear to have a way to 
resolve the disagreement or at least to move forward. Assuming the patient resides in a 
state that does not specify an order in which relatives should be identified as surrogates, 
we can split the decision making between the surrogates and encourage them to decide 
together. 
 
What might the analog of this solution look like in the case of PPPs? My suggestion, 
which for reasons of space I can only gesture to here, is straightforward: we should give 
equal weight to competing PPPs that are reasonable in the way identified above. Two 
PPPs will count as competitors in any given case when they deliver differing probabilistic 
judgments regarding a particular patient’s preferences over the available treatment 
options.18,19 Two comments are in order. First, what this means in practice is that we 
shall need to weigh the verdicts of competing PPPs by updating our prior credences 
about a patient’s preferences in the ordinary way by, for instance, conditionalizing on 
those competing verdicts as independent pieces of evidence. Second, the ethical benefit 
to patients of this approach should be clear. For notice that the trouble here is caused by 
the fact that there’s reasonable disagreement over which PPP—which way of solving 
the scope and weight problems—might be correct. But if that disagreement really is 
reasonable, then our practice ought to reflect the underlying normative uncertainty, and 
patients deserve treatment that does so. After all, patients might themselves reasonably 
have one or the other view of the matter. So an approach that instead simply plumped 
for one or the other PPP that delivered incompatible verdicts regarding a particular 
patient’s preferences on a particular occasion appears viciously arbitrary—not just from 
the theoretical point of view, but also from the point of view of patients themselves. 
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Of course, there is much more to say about the merits of (and problems with) this 
approach. And we shall still need some account of which ways of solving the scope and 
the weight problems count as reasonable as opposed to unreasonable (and so are taken 
into account in the way just suggested). That is a profitable direction for future 
theoretical research on the use of PPPs in clinical contexts. 
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